A potential novel treatment for cirrhosis-related ascites: Empagliflozin is safe and tolerable in advanced chronic liver disease.

Ivan ShenJana StojanovaMalcolm YeoNick OlsenIan LockartMax WangJan RoggeveldHiddo J L HeerspinkJerry R Greenfield Richard Osborne DayMark Danta

Published in: British journal of clinical pharmacology (2024)

Four-week treatment with empagliflozin was safe and well tolerated in patients with advanced chronic liver disease. These preliminary data support assessment of long-term treatment on disease-related and mortality outcomes in patients with cirrhosis through randomized control trials.

Keyphrases

type diabetes
clinical trial
cardiovascular disease
open label
combination therapy
cardiovascular events
skeletal muscle
study protocol